SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a clinical-stage precision oncology biotechnology company focused on discovering and developing alteration-specific therapeutics to target validated oncogenic drivers, today announced that the first clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant (ON/OFF) inhibitor, will be presented in a late-breaking oral presentation at t
